Baltieri Danilo Antonio, de Andrade Arthur Guerra
Program for Prevention of the Interdisciplinary Study Group of Alcohol and Drugs of the Psychiatric Institute of the Clinical Hospital of the Medical School of the University of São Paulo. São Paulo, SP, Brazil.
Braz J Psychiatry. 2003 Sep;25(3):156-9. doi: 10.1590/s1516-44462003000300007.
To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10.
Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication.
Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups.
Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.
评估阿坎酸对75名年龄在18至59岁、根据国际疾病分类第10版诊断为酒精依赖的男性患者的疗效和安全性。
双盲、安慰剂对照研究，为期24周。经过一周的脱毒期后，患者被随机分为两组：第一组接受阿坎酸（每日6片333毫克，共12周），第二组接受安慰剂（6片，共12周）。在最初的12周后，患者在无药物治疗的情况下继续随访12周。
与接受安慰剂治疗的患者相比，接受阿坎酸治疗的患者在24周治疗期内的持续戒酒时间显著更长（p = 0.017）。接受阿坎酸治疗的患者中有25%退出，接受安慰剂治疗的患者中有20%退出。两组均报告了很少的副作用。
阿坎酸被证明在治疗酒精依赖患者并在24周内维持戒酒状态方面是安全有效的。
